Can a triple threat of drug, immunotherapy, and radiation wipe out High-Risk urinary tract cancer before surgery?
NCT ID NCT07720921
First seen Jul 22, 2026 · Last updated Jul 23, 2026 · Updated 1 time
Summary
This phase 2 trial is testing whether a combination of an antibody-drug conjugate (disitamab vedotin), an immunotherapy (toripalimab), and targeted radiation can improve outcomes for people with high-risk upper tract urothelial carcinoma. Participants receive the drug and immunotherapy, followed by a short course of radiation, and then undergo surgery to remove the affected kidney and ureter. The main goal is to see if this approach can eliminate all signs of cancer in the surgical specimen.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- a combination of disitamab vedotin (an antibody-drug conjugate), toripalimab (an immunotherapy), and radiotherapy
- What this could lead to
- If successful, this approach could offer a more effective way to shrink or eliminate tumors before surgery, potentially improving outcomes for people with high-risk upper tract urothelial carcinoma.
- What could go wrong
- This is a small, early-phase trial with only 20 participants, so results may not apply broadly. The combination of drugs and radiation may cause significant side effects, and it is not yet known if it will improve long-term outcomes.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEOADJUVANT THERAPY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Departmeng of Urology, Peking University First Hospita
Beijing, Beijing Municipality, China
Contact Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a Triple-Drug attack before surgery eliminate more breast cancer in older women?
- Modified herpes virus joins forces with immunotherapy to attack head and neck tumors
- New targeted pill could boost lung cancer surgery success
- AI model could help doctors predict bladder cancer treatment outcomes
- New cocktail aims to shrink head and neck tumors before surgery
- Immunotherapy-Chemo cocktail shows promise for shrinking cervical tumors before surgery